The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does the EBMT support the development of CAR T therapies?

Feb 1, 2020

During the 2nd European CAR T Cell Meeting in Sitges, ES, the AML Global Portal was delighted to speak to Nicolaus Kröger, University Hospital Hamburg, Hamburg, DE. We asked: How does the EBMT support the development of CAR T therapies?

Nicolaus Kröger explains that the EBMT is highly committed to the development of CAR T cells. He tells us that EBMT has received a positive opinion by the European Medicines Agency thus the EBMT is open to register all CAR T cells around Europe. He also discusses the new registry that was established by the EBMT with CIBMTR to collect CAR T data. Lastly, he talks about the development of the CAR T cell governance structure, where all stakeholders form a group with the shared aim to develop CAR T cells in Europe.

How does the EBMT support the development of CAR T therapies?